1. Home
  2. Directory
  3. California
  4. Burbank
  5. Optometrist
  6. NPI Profile
  7. Prescriptions 1992886113

DR. SARA SRBUI HAKOPIAN O.D.
Prescription History 1992886113
Optometrist in Burbank, CA

NPI Status: Active since October 17, 2006

Contact Information

421 E ANGELENO AVE STE 101
BURBANK, CA
ZIP 91501
Phone: (818) 556-3600
Fax: (818) 556-3600

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. SARA SRBUI HAKOPIAN O.D., an active Optometrist specialist practicing in Burbank, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 75 documented patient claims. Among these therapy options, the most frequently utilized medication is Restasis, which accounts for 25 claims alone.

Medication Index

N
O
R
X
No matching medications currently found on file.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 15.0
Days Supply 318
CA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply675
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.4% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $241.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$16.09

State Avg Cost Per Claim

$14.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Olopatadine Hcl

Generic Formulation: Olopatadine HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 13
30-Day Fills 16.0
Days Supply 480
CA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills48.1
Peer Average Days Supply1,274
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $277.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.38

State Avg Cost Per Claim

$48.72

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antihistamine used to treat itching and redness in the eyes due to allergies. This medication is not recommended for the treatment of eye irritation due to wearing contact lenses.

Restasis

Generic Formulation: CyclosporineSpecialty: Optometry
Provider Metrics Summary
Total Claims 25
30-Day Fills 28.0
Days Supply 840
CA State Average Benchmarks
Peer Average Claims85.0
Peer Average 30-Day Fills122.0
Peer Average Days Supply3,636
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.6% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,622.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$784.90

State Avg Cost Per Claim

$947.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection.

Therapeutic Applications

Cyclosporine eye drops are used to treat a certain type of dry eyes. They work by increasing the amount of tears you make.

Xiidra

Generic Formulation: LifitegrastSpecialty: Optometry
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 660
CA State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills66.4
Peer Average Days Supply1,993
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.2% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $16,725.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$760.24

State Avg Cost Per Claim

$938.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat dry eye disease.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. SARA SRBUI HAKOPIAN O.D. provides transparency into local medical care patterns within Burbank, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.